SEARCH

SEARCH BY CITATION

References

  • 1
    Parkin D,Bray F,Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
  • 2
    Deslauriers J. Current surgical treatment of non-small cell lung cancer 2001. Eur Respir J Suppl. 2002; 35: 61s-70s.
  • 3
    Arriagada R,Bergman B,Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med. 2004; 350: 351-360.
  • 4
    Winton T,Livingston R,Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. N Engl J Med. 2005; 352: 2589-2597.
  • 5
    Douillard J,Rosell R,Delena M, et al. ANITA: phase III adjuvant vinorelbine and cisplatin versus observation in completely resected (StageI-III) non-small cell lung cancer patients: final results after 70-month median follow-up [abstract 7013]. J Clin Oncol. 2005; 23: 624S.
  • 6
    Strauss GM,Herdon JE,Maddaus MA, et al. Adjuvant chemotherapy in Stage IB non-small cell lung cancer: update of CALGB protocol 9633 [abstract 7007]. J Clin Oncol. 2006; 24: 365S.
  • 7
    Calhoun R,Jablons D,Lau D, et al. Adjuvant treatment of Stage IB NSCLC. Oncology. 2008; 22: 511-516.
  • 8
    LeChevalier T,Dunant A,Arriagada R, et al. Long-term results of the International Adjuvant Lung Cancer Trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small cell lung cancer (NSCLC) [abstract 7507]. J Clin Oncol. 2008; 26: 398S.
  • 9
    Ginsberg RJ,Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995; 60: 615-623.
  • 10
    Kelsey CR,Light KL,Marks LB. Patterns of failure after resection of non-small-cell lung cancer: implications for postoperative radiation therapy volumes. Int J Radiat Oncol Biol Phys. 2006; 65: 1097-1105.
  • 11
    Kaplan ES,Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 475-480.
  • 12
    Cox DR. Regression models and life tables. JR Stat Soc B. 1972; 34: 187-220.
  • 13
    Shields TW. Prognostic significance of parenchymal lymphatic vessel and blood vessel invasion in carcinoma of the lung. Surg Gyn Obstet. 1983; 157: 185-190.
  • 14
    Brechot JM,Chevret S,Charpentier MC, et al. Blood vessel and lymphatic vessel invasion in resected non-small cell lung carcinoma: correlation with TNM stage and disease free and overall survival. Cancer. 1996; 78: 2111-2118.
  • 15
    Goldstein NS,Mani A,Chmielewski G, et al. Prognostic Factors in T1N0M0 adenocarcinomas and bronchioloalveolar carcinomas of the lung. Am J Clin Pathol. 1999; 112: 391-402.
  • 16
    Cagini L,Monacelli M,Giustozzi G, et al. Biological prognostic factors for early stage completely resected non-small lung cancer. J Surg Oncol. 2000; 74: 53-60.
  • 17
    Kwiatkowski DJ,Harpole DH,Godleski J, et al. Molecular pathologic substaging in 244 Stage I non-small cell lung cancer patients: clinical implications. J Clin Oncol. 1998; 16: 2468-2477.
  • 18
    Bianchini F,Kaaks R,Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002; 3: 565-574.
  • 19
    Callee EE,Rodriguez C,Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348: 1625-1638.
  • 20
    Park SM,Lim MK,Jung KW, et al. Prediagnosis smoking, obesity, insulin resistance, and second primary cancer risk in male cancer survivors: National Health Insurance Corporation Study. J Clin Oncol. 2007; 25: 4835-4843.
  • 21
    Dawson SI. Long-term risk of malignant neoplasm associated with gestational glucose intolerance. Cancer. 2004; 100: 149-155.
  • 22
    Hsing AW,Gao YT,Chua S, et al. Insulin resistance and prostate cancer risk. J Natl Cancer Inst. 2003; 95: 67-71.
  • 23
    Jee SH,Ohrr H,Sull JW, et al. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005; 293: 194-202.
  • 24
    Gapstur SM,Gann PH,Lowe W, et al. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA. 2000; 283: 2552-2558.
  • 25
    Govindarajan R,Ratnasinghe L,Simmons DL, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol. 2007; 25: 1476-1481.
  • 26
    Hazra S,Batra RK,Tai HH, et al. Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol. 2007; 71: 1715-1720.
  • 27
    Feng Y,Busaidy N,Lee M, et al. Differential impact of anti-diabetic treatments on pancreatic cancer cell growth in cell culture conditions mimicking different stages in the natural history of diabetes mellitus type 2 [abstract 4640]. J Clin Oncol. 2008; 26: 248S.
  • 28
    Jiralerspong S,Giordano SH,Meric-Bernstam F, et al. The effects of metformin on pathologic complete response (pCR) rates in diabetic breast cancer(BC) patients receiving neoadjuvant systemic therapy [abstract 528]. J Clin Oncol. 2008; 26: 13S.
  • 29
    Pairolero PC,Williams DE,Bergstralh EJ, et al. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg. 1984; 38: 331-338.
  • 30
    Blanchon F,Grivaux M,Asselain B, et al. 4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. Lancet Oncol. 2006; 7: 829-836.
  • 31
    Mountain CF. New prognostic factors in lung cancer. Biologic prophets of cancer cell aggression. Chest. 1995; 108: 246-254.
  • 32
    van Rens MT,de la Riviere AB,Elbers HR, et al. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest. 2000; 117: 374-379.
  • 33
    Deslauriers J,Gregoire J,Jacques LF, et al. Sleeve lobectomy versus pneumonectomy for lung cancer: a comparative analysis of survival and sites or recurrences. Ann Thorac Surg. 2004; 77: 1152-1156.
  • 34
    Varlotto JM,Flickinger JC,Recht A, et al. A comparison of survival and disease-specific survival in surgically resected, lymph node-positive bronchioloalveolar carcinoma versus nonsmall cell lung cancer: implications for adjuvant therapy. Cancer. 2008; 112: 1547-1554.
  • 35
    Varlotto JM,Flickinger JC,Medford-Davis LN, et al. Factors associated with local, distant, overall recurrence in surgically-resected non-small cell lung cancer and the role of diabetes in local recurrence [abstract 7572]. J Clin Oncol. 2008; 26: 415S.
  • 36
    Shaw EG,Brindle JS,Creagan ET, et al. Locally recurrent non-small-cell lung cancer after complete surgical resection. Mayo Clin Proc. 1992; 67: 1197-1200.
  • 37
    Yano T,Hara N,Ichinose Y, et al. Local recurrence after complete resection for non-small-cell carcinoma of the lung. Significance of local control by radiation treatment. J Thorac Cardiovasc Surg. 1994; 107: 8-112.
  • 38
    Westeel V,Choma D,Clement F. Relevance of an intensive postoperative follow-up after surgery for non-small cell lung cancer. Ann Thorac Surg. 2000; 70: 1185-1190.
  • 39
    Ettinger DS,Ackerley W,Bepler G, et al. National Comprehensive Cancer Network. Practice guidelines in oncology – v. 2.2008. Fort Washington, PA: NCCN.